Highest-materiality recent filing
GeoVax Labs receives Nasdaq delisting notice for failing $2.5M stockholders' equity rule
Nasdaq notified GeoVax on July 7, 2026 of non-compliance with minimum $2,500,000 stockholders' equity requirement (Listing Rule 5550(b)(1)).
GeoVax prices $3M private placement offering at $1.4799 per unit with warrants
Gross proceeds ~$3M; net proceeds ~$2.7M after placement agent fees and expenses.
GeoVax Q1 2026 net loss $5.3M; cash $1.3M; advances GEO-MVA Phase 3
Net loss of $5.3M for Q1 2026 vs $5.4M in Q1 2025; no revenue vs $1.6M prior (BARDA contract terminated).
GeoVax reports 2025 net loss $21.5M; Phase 3 trial for mpox vaccine planned H2 2026
Net loss $21.5M ($22.40/share) vs $25.0M ($120.46/share) in 2024; revenue $2.5M from BARDA contract.
GeoVax raises ~$1M gross in registered direct offering priced at $2.31/share
Offering of 432,902 shares (or pre-funded warrants) at $2.31/share; net proceeds ~$865,000.
GeoVax Labs effects 1-for-25 reverse stock split effective January 9, 2026
Each 25 shares of common stock automatically combined into 1 share; no fractional shares issued.
GeoVax raises ~$3.2M in public offering of 13.2M units at $0.245/unit
Offering of 13,244,896 common units at $0.245/unit, each consisting of one share plus warrants for two shares.
GeoVax Q3 net loss $6.3M ($0.31/sh); BARDA contract terminated; Mpox vaccine accelerated
Net loss of $6.3M vs $5.8M in Q3 2024; per-share loss improved to $0.31 from $0.91 due to share count change.
GeoVax raises ~$2.5M in registered direct offering; issues shares and warrants at $0.63
3,968,256 shares sold at $0.63 each with warrants to buy 11,904,768 shares at $0.63.
GeoVax receives Nasdaq deficiency notice for bid price below $1.00
Nasdaq notified GeoVax on July 31, 2025, that closing bid price was below $1.00 for 30 consecutive business days.
GeoVax raises ~$6M in public offering of 9.2M units at $0.65/unit
Offering of 9,235,000 units at $0.65/unit, each unit = 1 share + warrant to buy 2 shares.
GeoVax Q1 net loss narrows to $5.4M; BARDA award ended, COVID vaccine data due Q2 2025
Net loss $5.4M (vs $5.9M Q1 2024); revenue $1.6M from BARDA contract (none prior year).
BARDA terminates GeoVax's Phase 2b COVID-19 vaccine contract for convenience
On April 11, 2025, GeoVax received stop-work notice from ATI/BARDA for Project Agreement RRPV-24-04-NGVx-006.
GeoVax FY2024 net loss $25.0M; BARDA award yields $4.0M revenue; key trials advancing
Net loss $25.0M vs $26.0M in 2023; revenue of $4.0M from BARDA Project NextGen contract (no revenue in 2023).
GeoVax Labs raises $4.5M in registered direct offering, amends existing warrants
Issued 3,435,115 shares or equivalents and common warrants at $1.31/unit, gross proceeds ~$4.5M.
GeoVax Labs regains Nasdaq compliance with $8.5M stockholders' equity
Received Nasdaq notice on Nov 18, 2024 confirming compliance with Listing Rule 5550(b)(1) based on $8,503,876 stockholders' equity as of Sep 30, 2024.
GeoVax Q3 net loss $5.8M ($0.91/share); BARDA NextGen trial on track; special meeting adjourned
Net loss $5.8M for Q3 2024 ($0.91/share) vs $8.4M ($4.75/share) in Q3 2023; nine-month net loss $16.7M ($4.52/share).
GeoVax Labs boosts ATM equity offering capacity from $4.5M to $30M
Maximum aggregate offering price under Sales Agreement with A.G.P./Alliance Global Partners increased from $4,486,846 to $30,000,000.
GeoVax raises ~$5.0M in registered direct offering at $5.125/share with warrants
Offering of 837,500 common shares at $5.125/share and 138,110 pre-funded warrants at $5.12499, exercise price $0.0001.
GeoVax raises ~$8.5M in registered direct offering of 1.7M shares at $5.00 each
Gross proceeds $8.5M; net proceeds ~$7.855M after fees and expenses.
GeoVax reports Q2 net loss of $5.1M; awarded up to $388M BARDA contract for COVID vaccine trial
Net loss $5.1M ($1.99/share) vs $5.9M ($3.79) in Q2 2023; R&D expenses $4.3M.
GeoVax raises ~$3.1M gross in offering of stock, pre-funded and common warrants
Offering of 1,085,000 shares (or equivalents) at $2.86; pre-funded warrants for 626,368 shares and common warrants for 2,170,000 shares.
GeoVax receives BARDA award up to $45M for Phase 2b COVID-19 vaccine trial
Direct award to GeoVax of ~$24.3M, potentially increasing to $45M, for manufacturing and clinical trial support.
GeoVax Labs receives Nasdaq delisting notice for failing $2.5M equity minimum
Notice received May 23, 2024; stockholders' equity as of March 31, 2024 below $2.5M requirement.
GeoVax Q1 net loss widens to $5.6M; cash drops to $0.8M, raising going-concern risk
Net loss of $5.6M ($2.47 per share) vs $4.0M ($2.30 per share) in Q1 2023.
GeoVax reports 2023 net loss of $26.0M, cash drops to $6.5M; pipeline advances
Net loss widened to $26.0M in 2023 from $14.0M in 2022, driven by higher R&D costs ($20.7M vs $9.1M).
GeoVax regains Nasdaq compliance after reverse stock split, delisting cancelled
Received Nasdaq delisting notice Dec 6, 2023 for bid price below $1.00.
GeoVax Labs effects 1-for-15 reverse stock split, authorized shares cut to 150M
1-for-15 reverse stock split effective January 30, 2024; no fractional shares issued.
GeoVax shareholders approve authorized share reduction and reverse stock split
Authorized shares reduced from 600M to 150M; vote: 11.2M for, 2.4M against.
GeoVax receives Nasdaq delisting notice for bid price under $1; will appeal, plans reverse split
On Dec 6, 2023, Nasdaq notified GeoVax that its common stock failed to maintain minimum $1 bid price (Nasdaq Rule 5550(a)(2)).
GeoVax raises ~$4.37M via warrant inducement; issues new warrants for 21.1M shares at $0.414
Existing warrants for 10.6M shares exercised at reduced price $0.414/share, gross proceeds ~$4.37M.
GeoVax Q3 net loss widens to $8.4M; Phase 2 COVID vaccine enrollment completed
Net loss $8.4M ($0.32/share) vs $3.97M ($0.17/share) in Q3 2022; cash $12.7M at Sep 30 vs $27.6M at Dec 31.
GeoVax Q2 2023 net loss widens to $5.93M ($0.22/sh); cash at $17.8M
Net loss for Q2 2023 was $5.93M ($0.22/sh) vs $2.24M ($0.18/sh) in Q2 2022.
GeoVax Labs enters ATM equity offering agreement for up to $6.529M
Company may sell up to $6,529,000 of common stock at market prices via H.C. Wainwright as sales agent.
On December 7, 2022, our Board of Directors (the “Board”) appointed Jayne Morgan, M.D. to the Board, effective as of December 7, 2022.
On August 31, 2022, our Board of Directors (the “Board”) appointed Nicole Lemerond to the Board, effective as of August 31, 2022.
Max materiality 0.85 · Median 0.60 · Most common event other_material